VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

September 8, 2015

Primary Completion Date

October 22, 2019

Study Completion Date

March 7, 2023

Conditions
Bladder Cancer
Interventions
DRUG

VPM1002BC

"Phase 1:~Induction: 6 intravesical instillations of VPM1002BC in 6-12 weeks (dose de-escalation in cohorts of 3-6 patients)~Phase 2:~Induction: VPM1002BC at RP2D established in phase I, 6 intravesical instillations in 6-12 weeks (n=39 including patients treated at RPD2 in phase I)"

Trial Locations (16)

1011

Centre hospitalier universitaire vaudois CHUV, Lausanne

1211

Hôpitaux Universitaires de Genève, Geneva

3010

Inselspital, Bern, Bern

4031

Universitaetsspital-Basel, Basel

5001

Kantonsspital Aarau, Aarau

5404

Kantonsspital Baden, Baden

6500

Istituto Oncologico della Svizzera Italiana - Ospedale Regionale Bellinzona e Valli, Bellinzona

6600

Fondazione Oncologia Lago Maggiore, Locarno

7000

Kantonsspital Graubuenden, Chur

9007

Kantonsspital St. Gallen, Sankt Gallen

44625

Universitätsklinikum der Ruhr-Universität Bochum, Herne

55131

Universitätsmedizin der Johannes Gutenberg Universität Mainz, Mainz

79106

Universitätsklinikum Freiburg, Freiburg im Breisgau

90419

Klinikum Nürnberg - Universitätsklinik der Paracelsus Medizinischen Privatuniversität, Nuremberg

93053

Uniklinik Regensburg, Regensburg

07747

Universitätsklinikum Jena, Jena

All Listed Sponsors
lead

Swiss Cancer Institute

OTHER

NCT02371447 - VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer | Biotech Hunter | Biotech Hunter